India, April 27 -- Oruka Therapeutics, Inc. (ORKA) shares jumped 21.79 percent to $84.14, gaining $15.11 on Monday, after reporting strong interim Phase 2a clinical data for its lead drug candidate in psoriasis.
The stock is currently trading at $84.14, compared to a previous close of $69.03 on the Nasdaq. It reached an intraday high of $91.00 and a low of $82.18, with trading volume of 3.72 million shares.
The company announced positive results from its EVERLAST-A trial evaluating ORKA-001, a next-generation IL-23p19 monoclonal antibody for moderate-to-severe plaque psoriasis. The data showed that 63.5 percent of treated patients achieved complete skin clearance at Week 16, with 83 percent reaching PASI 90, highlighting robust efficacy....